Insurance Corporation, 550 17th Street NW., Washington, DC 20429.

Comments: Comments on this collection of information are welcome and should be submitted before November 4, 1991.

ADDRESSES: A copy of the submission may be obtained by calling or writing the FDIC contact listed above. Comments regarding the submission should be addressed to both the OMB reviewer and the FDIC contact listed above.

SUPPLEMENTARY INFORMATION: Insured state nonmember banks are required by law to obtain the consent of the FDIC prior to reducing or retiring any part of their common or preferred stock, or retiring any part of their capital notes or debentures. To obtain that consent, the banks submit letter applications to the FDIC.

Dated: August 29, 1991.

Federal Deposit Insurance Corporation.

Hoyle L. Robinson,

Executive Secretary.

[FR Doc. 91-21288 Filed 9-4-91; 8:45 am]

BILLING CODE 6714-01-M

FEDERAL MARITIME COMMISSION

Columbus/Pace Space Charter and Sailing Agreement; Agreement(s) Filed

The Federal Maritime Commission hereby gives notice of the filing of the following agreement(s) pursuant to section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal Maritime Commission, 1100 L Street, NW., room 10325. Interested parties may submit comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments are found in § 572.603 of title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Agreement No.: 212-010746-005.

Title: Columbus/Pace Space Charter and Sailing Agreement.

Parties:

Hamburg-Sudamerikanische Dampfschifffahrts-Gesellschaft Eggert & Amsinck (Columbus Line),
Associated Container Transportation (Australia), Limited.

Synopsis: The proposed amendment would add Blue Star Pace Ltd. ("Pace") as a party and delete Associated Container Transportation (Australia), Limited ("Acta") as a party to the Agreement. It would also revise the membership provision waiving the 90 days' written notice of withdrawal by the unanimous consent of the parties. The parties have requested a shortened review period.

Agreement No.: 202-010776-061.

Title: Asia North America Eastbound Rate Agreement.

Parties:

American President Lines, Ltd.,
Kawasaki Kisen Kaisha, Ltd.,
A.P. Moller-Maersk Line,
Mitsui O.S.K. Lines, Ltd.,
Neptune Orient Lines, Ltd.,
Nippon Liner System, Ltd.,
Nippon Yusen Kaisha Line,
Sea-Land Service, Inc.

Synopsis: The proposed amendment would delete Canada from the geographic scope and delete other references to Canada in the Agreement.

Agreement No.: 203-011211-006.

Title: Transpacific Discussion Agreement.

Parties:

American President Lines, Ltd.,
Evergreen Marine Corp. (Taiwan) Ltd.,
Hanjin Shipping Co., Ltd.,
Hyundai Merchant Marine Co., Ltd.,
Kawasaki Kisen Kaisha, Ltd.,
A.P. Moller-Maersk Line,
Mitsui O.S.K. Lines, Ltd.,
Neptune Orient Lines, Ltd.,
Nippon Liner System, Ltd.,
Nippon Yusen Kaisha,
Orient Overseas Container Line, Inc.,
Sea-Land Service, Inc.,
Yangming Marine Transport Corp.

Synopsis: The proposed amendment would delete Nippon Liner System as a party to the Agreement effective October 1, 1991. It would also make other nonsubstantive changes.

Agreement No.: 203-011223-005.

Title: Transpacific Stabilization Agreement.

Parties:

American President Lines, Ltd.,
Evergreen Marine Corp. (Taiwan) Ltd.,
Hanjin Shipping Co., Ltd.,
Hyundai Merchant Marine Co., Ltd.,
Kawasaki Kisen Kaisha, Ltd.,
A.P. Moller-Maersk Line,
Mitsui O.S.K. Lines, Ltd.,
Neptune Orient Lines, Ltd.,
Nippon Liner System, Ltd.,
Nippon Yusen Kaisha,
Orient Overseas Container Line, Inc.,
Sea-Land Service, Inc.,
Yangming Marine Transport Corp.

Synopsis: The proposed amendment would delete Nippon Liner System, Ltd. as a party to the Agreement. It would also make other nonsubstantive changes.

Agreement No.: 224-200165-003.

Title: Maryland Port Administration/Ceres Corporation Terminal Leasing Agreement.

Parties:

Maryland Port Administration,
Ceres Corporation.

Synopsis: The proposed amendment, filed August 26, 1991, would eliminate 8.48 acres in Area 1602 and substitute 10.06 acres in Area 501 of the Dundalk Marine Terminal.

Dated: August 29, 1991.

By Order of the Federal Maritime Commission.

Ronald D. Murphy,

Assistant Secretary.

[FR Doc. 91-21216 Filed 9-4-91; 8:45 am]

BILLING CODE 6730-01-M

City of Los Angeles/Pasha Maritime Services, Inc.; Agreement(s) Filed

The Federal Maritime Commission hereby gives notice that the following agreement(s) has been filed with the Commission pursuant to section 15 of the Shipping Act, 1916, and section 5 of the Shipping Act of 1984.

Interested parties may inspect and obtain a copy of each agreement at the Washington, DC Office of the Federal Maritime Commission, 1100 L Street, NW., room 10325. Interested parties may submit protests or comments on each agreement to the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days after the date of the **Federal Register** in which this notice appears. The requirements for comments and protests are found in § 560.7 and/or 572.603 of title 46 of the Code of Federal Regulations. Interested persons should consult this section before communicating with the Commission regarding a pending agreement.

Any person filing a comment or protest with the Commission shall, at the same time, deliver a copy of that document to the person filing the agreement at the address shown below.

Agreement No.: 224-011078-001.

Title: City of Los Angeles/Pasha Maritime Services, Inc. Terminal Agreement.

Parties: City of Los Angeles Board of Harbor Commissioners, Pasha Maritime Services.

Filing Party: Catherine H. Vale, Esq., Assistant City Attorney, City of Los Angeles, P.O. Box 151, San Pedro, CA 90733.

Synopsis: The proposed amendment, filed August 23, 1991, would extend the Agreement through December 31, 1995 and would adjust the compensation payable during the extended term of the Agreement.

Dated: August 29, 1991.

By Order of the Federal Maritime Commission.

Ronald D. Murphy,

Assistant Secretary.

[FR Doc. 91-21217 Filed 9-4-91; 8:45 am]

BILLING CODE 6730-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 91F-0228]

Eastman Chemical Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Eastman Chemical Co., Division of Eastman Kodak Co., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of sucrose acetate isobutyrate as a stabilizer of emulsions of flavoring oils used in nonalcoholic carbonated and noncarbonated beverages for human consumption.

FOR FURTHER INFORMATION CONTACT: Blondell Anderson, Center for Food Safety and Applied Nutrition (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-426-8950.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1A4266) has been filed by Eastman Chemical Co., Division of Eastman Kodak Co., P.O. Box 511, Kingsport, TN 37662. The petition proposes to amend the food additive regulations to provide for the safe use of sucrose acetate isobutyrate as a stabilizer of emulsions of flavoring oils used in nonalcoholic carbonated and noncarbonated beverages for human consumption.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 28, 1991.

Douglas L. Archer,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-21223 Filed 9-4-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91F-0286]

Healthy Business, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Healthy Business, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of Polysorbate 80, disodium EDTA, and sodium lauryl sulfate as components of a fruit and vegetable wash.

FOR FURTHER INFORMATION CONTACT: Wesley R. Long, Center for Food Safety and Applied Nutrition (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-426-9463.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1A4255) has been filed by Healthy Business, Inc., 695 South Colorado Blvd., Denver, CO 80222. The petition proposes to amend the food additive regulations in § 173.315 Chemicals used in washing or to assist in the lye peeling of fruits and vegetables (21 CFR 173.315) to provide for the safe use of Polysorbate 80, disodium EDTA, and sodium lauryl sulfate as components of a fruit and vegetable wash.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 28, 1991.

Douglas L. Archer,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-21224 Filed 9-4-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91P-0269]

Cottage Cheese Deviating From Identity Standard; Temporary Permit for Market Testing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a temporary permit has been issued to Ludwig Dairy Corp. to market test a product designated as "nonfat cottage cheese" that deviates from the U.S. standards of identity for cottage cheese (21 CFR 133.128), dry curd cottage cheese (21 CFR 133.129), and lowfat cottage cheese (21 CFR 133.131). The purpose of the temporary permit is to allow the applicant to measure consumer acceptance of the product, identify mass production problems, and assess commercial feasibility.

DATES: This permit is effective for 15 months, beginning on the date the food is introduced or caused to be introduced into interstate commerce, but not later than December 4, 1991.

FOR FURTHER INFORMATION CONTACT: Michelle A. Smith, Center for Food Safety and Applied Nutrition (HFF-414), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-485-0106.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 130.17 concerning temporary permits to facilitate market testing of foods deviating from the requirements of the standards of identity promulgated under section 401 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 341), FDA is giving notice that a temporary permit has been issued to Ludwig Dairy Corp., 1309 West 7th St., Dixon, IL 61021.

The permit covers limited interstate marketing tests of a nonfat cottage cheese, formulated from dry curd cottage cheese and a dressing, such that the finished product contains less than 0.3 percent milkfat. The food deviates from the U.S. standards of identity for cottage cheese (21 CFR 133.128) and lowfat cottage cheese (21 CFR 133.131) in that the milkfat content of cottage cheese is not less than 4.0 percent, and the milkfat content of lowfat cottage cheese ranges from 0.5 to 2.0 percent. The test product also deviates from the U.S. standard of identity for dry curd cottage cheese (21 CFR 133.129) because of the added dressing. The test product meets all requirements of the standards with the exception of these deviations. The purpose of the variation is to offer the consumer a product that is

nutritionally equivalent to cottage cheese products with dressing but contains less fat.

For the purpose of this permit, the name of the product is "nonfat cottage cheese." In accordance with FDA's current views, "fat free" food labeling is acceptable because the product contains less than 0.5 gram (g) fat per 113 g (4-ounce) serving. The information panel of the label will bear nutrition labeling in accordance with 21 CFR 101.9.

This permit provides for the temporary marketing of 90,900 kilograms (200,000 pounds) of the test product. The product will be manufactured at Ludwig Dairy Corp., 1309 West 7th St., Dixon, IL 61021, and distributed in Illinois, Indiana, and Wisconsin.

Each of the ingredients used in the food must be declared on the label as required by the applicable sections of 21 CFR part 101. This permit is effective for 15 months, beginning on the date the food is introduced or caused to be introduced into interstate commerce, but not later than December 4, 1991.

Dated: August 28, 1991.

Douglas L. Archer,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91-21225 Filed 9-4-91; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 91N-0263]

Bolar Pharmaceutical Co., Inc.; Withdrawal of Approval of Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 142 abbreviated new drug applications (ANDA's). Bolar Pharmaceutical Co., Inc., 33 Ralph Ave., Copiague, NY 11726-0030, requested that the agency withdraw approval of these ANDA's under a plea agreement with the United States Attorney's Office for the District of Maryland and the Office of Consumer Litigation of the Department of Justice.

EFFECTIVE DATE: October 7, 1991.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD-360), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8038.

SUPPLEMENTARY INFORMATION: Bolar Pharaceutical Co., Inc., the holder of the ANDA's listed in the table in this document, has asked FDA to withdraw approval of the ANDA's as part of a plea agreement with the United States Attorney's Office for the District of Maryland and the Office of Consumer Litigation of the Department of Justice.

ANDA No.	Drug
70-240	Disopyramide Phosphate Capsules, 100 milligrams (mg).
70-241	Disopyramide Phosphate Capsules, 150 mg.
70-242	Tolazamide Tablets, 100 mg.
70-243	Tolazamide Tablets, 250 mg.
70-244	Tolazamide Tablets, 500 mg.
70-245	Methyldopa Tablets, 125 mg.
70-246	Methyldopa Tablets, 250 mg.
70-247	Methyldopa Tablets, 500 mg.
70-363	Metoclopramide Hydrochloride Tablets, 10 mg.
70-365	Methyldopa and Hydrochlorothiazide Tablets, 250 mg/15 mg.
70-366	Methyldopa and Hydrochlorothiazide Tablets, 250 mg/25 mg.
70-367	Methyldopa and Hydrochlorothiazide Tablets, 500 mg/30 mg.
70-368	Methyldopa and Hydrochlorothiazide Tablets, 500 mg/50 mg.
70-373	Perphenazine and Amitriptyline Hydrochloride Tablets, 2 mg/10 mg.
70-374	Perphenazine and Amitriptyline Hydrochloride Tablets, 2 mg/25 mg.
70-375	Perphenazine and Amitriptyline Hydrochloride Tablets, 4 mg/10 mg.
70-376	Perphenazine and Amitriptyline Hydrochloride Tablets, 4 mg/25 mg.
70-377	Perphenazine and Amitriptyline Hydrochloride Tablets, 4 mg/50 mg.
70-378	Propranolol Hydrochloride Tablets, 10 mg.
70-379	Propranolol Hydrochloride Tablets, 20 mg.
70-380	Propranolol Hydrochloride Tablets, 40 mg.
70-381	Propranolol Hydrochloride Tablets, 60 mg.
70-382	Propranolol Hydrochloride Tablets, 80 mg.
70-383	Temazepam Capsules, 15 mg.
70-384	Temazepam Capsules, 30 mg.
70-395	Clonidine Hydrochloride Tablets, 0.1 mg.
70-396	Clonidine Hydrochloride Tablets, 0.2 mg.
70-397	Clonidine Hydrochloride Tablets, 0.3 mg.
70-398	Propoxyphene Napsylate and Acetaminophen Tablets, 50 mg/325 mg.
70-399	Propoxyphene Napsylate and Acetaminophen Tablets, 100 mg/650 mg.
70-407	Lithium Carbonate Capsules, 300 mg.
70-784	Indomethacin Capsules, 25 mg.
70-785	Indomethacin Capsules, 50 mg.
71-112	Trazodone Hydrochloride Tablets, 50 mg.
71-113	Trazodone Hydrochloride Tablets, 100 mg.
71-374	Haloperidol Tablets, 5 mg.
71-375	Haloperidol Tablets, 10 mg.
71-376	Haloperidol Tablets, 20 mg.
71-571	Haloperidol Tablets, 0.5 mg.
71-572	Haloperidol Tablets, 1 mg.
71-573	Haloperidol Tablets, 2 mg.
71-943	Maprotiline Hydrochloride Tablets, 25 mg.
71-944	Maprotiline Hydrochloride Tablets, 50 mg.
71-945	Maprotiline Hydrochloride Tablets, 75 mg.
72-269	Timolol Maleate Tablets, 5 mg.
72-270	Timolol Maleate Tablets, 10 mg.
72-271	Timolol Maleate Tablets, 20 mg.
72-485	Oxybutynin Chloride Tablets, 5 mg.
80-401	Isoniazid Tablets, 100 mg.
83-178	Isoniazid Tablets, 300 mg.
83-179	Dicyclomine Hydrochloride Capsules, 10 mg.
83-221	Probenecid and Colchicine Tablets, 500 mg/0.5 mg.
83-456	Hydrochlorothiazide Tablets, 50 mg.
83-458	Hydrochlorothiazide Tablets, 25 mg.
83-462	Trichlormethiazide Tablets, 4 mg.
83-605	Methocarbamol Tablets, 500 and 750 mg.
83-770	Reserpine, Hydralazine Hydrochloride, and Hydrochlorothiazide Tablets, 0.1 mg/25 mg/15 mg.
83-795	Procainamide Hydrochloride Capsules, 250, 375, and 500 mg.
84-026	Chlorothiazide Tablets, 500 mg.
84-252	Imipramine Hydrochloride Tablets, 10, 25, and 50 mg.
84-303	Orphenadrine Citrate Sustained Release Tablets, 100 mg.
84-357	Procainamide Hydrochloride Capsules, 500 mg.
84-361	Dicyclomine Hydrochloride Tablets, 20 mg.
84-457	Dexamethasone Tablets, 0.75 mg.
84-498	Acetazolamide Tablets, 125 and 250 mg.
84-930	Ergoloid Mesylates Sublingual Tablets, 0.5 mg.
85-052	Primidone Tablets, 250 mg (Human).
85-053	Sulfamethoxazole Tablets, 500 mg.
85-099	Hydrochlorothiazide Tablets, 100 mg.
85-105	Trihexyphenidyl Hydrochloride Tablets, 5 mg.
85-117	Trihexyphenidyl Hydrochloride Tablets, 2 mg.
85-165	Chlorothiazide Tablets, 250 mg.
85-177	Ergoloid Mesylates Sublingual Tablets, 1 mg.
85-178	Prochlorperazine Maleate Tablets, 10 mg.
85-220	Imipramine Hydrochloride Tablets, 10 mg.
85-221	Imipramine Hydrochloride Tablets, 50 mg.
85-228	Bethanechol Chloride Tablets, 10 mg.
85-229	Bethanechol Chloride Tablets, 25 mg.
85-230	Bethanechol Chloride Tablets, 5 mg.
85-245	Cyproheptadine Hydrochloride Tablets, 4 mg.
85-317	Reserpine and Hydrochlorothiazide Tablets, 0.125 mg/25 mg.
85-373	Hydralazine Hydrochloride and Hydrochlorothiazide Tablets, 25 mg/15 mg.
85-440	Hydralazine Hydrochloride and Hydrochlorothiazide Capsules, 100 mg/50 mg.
85-446	Hydralazine Hydrochloride and Hydrochlorothiazide Capsules, 50 mg/50 mg.
85-457	Hydralazine Hydrochloride and Hydrochlorothiazide Capsules, 25 mg/25 mg.
85-476	Methyclothiazide Tablets, 5.0 mg.
85-487	Methyclothiazide Tablets, 2.5 mg.
85-562	Glycopyrrolate Tablets, 1 mg.
85-579	Prochlorperazine Maleate Tablets, 25 mg.
85-580	Prochlorperazine Maleate Tablets, 5 mg.
85-755	Liothyronine Sodium Tablets, 25 mg.
85-973	Trifluoperazine Hydrochloride Tablets, 5 mg.
85-974	Spironolactone/Hydrochlorothiazide Tablets, 25 mg/25 mg.
85-975	Trifluoperazine Hydrochloride Tablets, 1 mg.
85-976	Trifluoperazine Hydrochloride Tablets, 2 mg.
86-048	Isosorbide Dinitrate Oral Tablets, 20 mg.